deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT05249101

A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma

A Phase 1b/2, Dose-escalation, Randomized, Multicenter Study of Maintenance Ivaltinostat Plus Capecitabine or Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on FOLFIRINOX

Sponsor: CG Pharmaceuticals, Inc

Conditions Metastatic Pancreatic Adenocarcinoma
Interventions Capecitabine Ivaltinostat
Updated 15 times since 2022 Last updated: Dec 17, 2025 Started: Aug 15, 2022 Primary completion: Jun 30, 2026 Completion: Jul 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Metastatic Pancreatic Adenocarcinoma, this trial is ongoing. The trial is conducted by CG Pharmaceuticals, Inc and has accumulated 15 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Mar 2022 – ~Sep 2022 · 6 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Jan 2023 · 2 months · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Aug 2023 · 3 months · monthly snapshot~Aug 2023 – ~Nov 2023 · 3 months · monthly snapshot~Nov 2023 – ~Feb 2024 · 3 months · monthly snapshot~Feb 2024 – ~Jun 2024 · 4 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Jan 2026 · 11 months · monthly snapshot~Jan 2026 – present · 7 months · monthly snapshot

Change History

15 versions recorded

  1. Jan 2026 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Feb 2025 — Jan 2026 [monthly]

    Recruiting PHASE1/PHASE2

  3. Sep 2024 — Feb 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 10 earlier versions

  1. Feb 2024 — Jun 2024 [monthly]

    Recruiting PHASE1_PHASE2

  2. Nov 2023 — Feb 2024 [monthly]

    Recruiting PHASE1_PHASE2

  3. Aug 2023 — Nov 2023 [monthly]

    Recruiting PHASE1_PHASE2

  4. May 2023 — Aug 2023 [monthly]

    Recruiting PHASE1_PHASE2

  5. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE1_PHASE2

  6. Feb 2023 — Apr 2023 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE1_PHASE2

  8. Nov 2022 — Jan 2023 [monthly]

    Recruiting PHASE1_PHASE2

  9. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  10. Mar 2022 — Sep 2022 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • CG Pharmaceuticals, Inc
Data source: CG Pharmaceuticals, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Athens, United States , Buffalo, United States , Dallas, United States , Detroit, United States , Fairfax, United States , Hershey, United States , Houston, United States , Indianapolis, United States , Louisville, United States , New Orleans, United States and 6 more locations